Cifurtilimab (SEA-CD40), a nonfucosylated humanized IgG1 monoclonal antibody with agonistic properties, targets the CD40 receptor and demonstrates antitumor activities [1] [2].

Cifurtilimab enhances FcγRIIIa binding (10-fold higher than parental IgG1 antibodies), bolstering effector functions, resulting in a stronger immunostimulatory activity compared to antibodies with silenced or selective FcγR binding [1]. Exposure to Cifurtilimab elicits distinct response features, such as the activation of APCs, CD8+ and CD4+ T cells, NK cells, and targeted depletion of CD40+ B cells [1].

In preclinical murine models, the combined use of Cifurtilimab with chemotherapy agents enhanced antitumor activity [2].